Growth Hormone
Somapacitan vs. Norditropin® for Small for Gestational Age (SGA) Children
This trial is comparing two medicines to see if they are effective in treating children who were born small and stayed small. One medicine is given once a week, and the other is given once a day. The trial will last for four years, and participants will have nine clinic visits.
Standard Nasal Care + Oral Antibiotics for Antibiotics
To find out whether oral antibiotics given after transsphenoidal endoscopic surgery for pituitary adenoma improves sinus and nasal symptoms, reduces the incidence of infection (sinusitis), and helps mucosal healing in the nasal passages.
C-type natriuretic peptide analog
Vosoritide for Turner Syndrome
This trial tests vosoritide, a medication that helps bone growth, in young girls with Turner syndrome who are short. It aims to see if vosoritide can help them grow taller, especially if they haven't responded well to other treatments.
Popular Filters
Trials With No Placebo
Tyrosine Kinase Inhibitor
Infigratinib for Achondroplasia
This trial is testing a medicine called infigratinib in children aged 3 to 11 years with Achondroplasia. The medicine works by blocking proteins that cause abnormal bone growth. The children have already participated in an earlier study.
Frequently Asked Questions
Introduction to growth hormone deficiency
What are the top hospitals conducting growth hormone deficiency research?
When it comes to advancements in the field of growth hormone deficiency, several top hospitals are leading the way with their clinical trials. In Nashville, Vanderbilt University Medical Center is currently conducting two active trials focused on this condition. Although they do not have any all-time trials recorded yet, their dedication to research and innovation shows great promise for future breakthroughs. Meanwhile, at Children's National Hospital in Washington, researchers have also embarked on two active growth hormone deficiency trials. With a total of two all-time trials under their belt since starting their first investigation in 2020, they are making significant strides in understanding this complex condition.
The University of Iowa in Iowa City has joined the ranks with its own ongoing studies on growth hormone deficiency. They currently have two active clinical trials and have conducted three all-time trials thus far since launching their initial study back in 2017. Similarly situated at UMass Memorial Medical Center in Worcester where there are also engaged towards carrying out investigations for an equal number of current growth hormone deficiencies cases plus already adding up couple more experiments which makes them pioneers from initiating trial records until recent years near2009
Last but not least is Seattle Children's Hospital located right by the scenic landscapes of Seattle; it has likewise been actively involved by conducting two ongoing clinical tests that tackle growth hormone deficiency head-on.Even though being relatively new like others started around same period as wellin 2009 that hospital stands tall showcasing commitment via participating similar count-all time examination endeavors related to such conditions.
These dedicated hospitals across different locations demonstrate a shared goal of improving outcomes for individuals affected by growth hormone deficiency through cutting-edge research and compassionate care. With each trial conducted and every discovery made, these institutions bring us closer to a better understanding of this condition and potential treatments that can transform lives.
Which are the best cities for growth hormone deficiency clinical trials?
Seattle, Washington; New york, New York; Cincinnati, Ohio; Phoenix, Arizona; and Fort Worth, Texas emerge as key cities for growth hormone deficiency clinical trials. Seattle and New York share the highest number of active trials with 6 each. These studies investigate treatments like Lonapegsomatropin, Somatropin, LUM-201, Nivolumab, somapacitan, Infigratinib 0.128 mg/kg, Nasal saline irrigation plus Standard Nasal Care + Oral Antibiotics respectively. Meanwhile Cincinnati has 4 active trials studying somapacitan and others while Phoenix also has 4 active trials examining Lonapegsomatropin alongside other interventions. Lastly Fort Worth offers 3 active trials exploring GenSci004 in addition to LUM-201 and somapacitan among others. These cities provide opportunities for individuals with growth hormone deficiency to participate in cutting-edge clinical research aimed at improving treatment options and enhancing quality of life.
Which are the top treatments for growth hormone deficiency being explored in clinical trials?
Clinical trials are paving the way for breakthroughs in treating growth hormone deficiency. Among the top contenders is somapacitan, currently undergoing two active trials dedicated to this condition. Since its introduction in 2012, it has been enlisted in a total of eight growth hormone deficiency trials. Another frontrunner is lonapegsomatropin, which made its debut just last year but is already making waves with two ongoing clinical trials focused on addressing growth hormone deficiency. These innovative treatments demonstrate great promise and may offer new hope for individuals affected by this hormonal disorder.
What are the most recent clinical trials for growth hormone deficiency?
Groundbreaking clinical trials are shedding new light on the treatment of growth hormone deficiency. One recent study focused on LUM-201, administering a dosage of 1.6 mg/kg/day to individuals with this condition during its Phase 2 trial. Similarly, lonapegsomatropin underwent Phase 3 testing and displayed promising results for growth hormone deficiency patients. Another noteworthy trial involved rollover subjects in Arm 1, further contributing to our understanding of potential treatments for this condition during its Phase 2 stage. With these advancements in medical research, we move closer to developing innovative therapies that can improve the lives of those affected by growth hormone deficiency.
What growth hormone deficiency clinical trials were recently completed?
Recently completed clinical trials have made significant strides in addressing growth hormone deficiency. In December 2017, Ascendis Pharma A/S concluded a trial that focused on TransCon hGH therapy. This breakthrough treatment offers hope for individuals with growth hormone deficiencies and showcases the dedication of researchers in advancing medical interventions for this condition.